All In Biotech

Drug Trial Radar · NCT06401616

Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)

Anticoagulant Therapy in Patients With Atrial Fibrillation After Surgical Left Atrial Appendage Closure: a Randomized Non-inferiority Trial (The ATLAAC Trial)

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,220 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,220

Planned (sponsor's estimate)

Start

May 21, 2024

Primary completion

Mar 1, 2028

Study completion Mar 1, 2028

Sponsor

Lead sponsor
Odense University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Copenhagen University Hospital, Rigshospitalet; Gødstrup Hospital; Aarhus University Hospital; Aalborg University Hospital; Population Health Research Institute; Region of Southern Denmark
First posted
May 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Left atrial appendage (LAA) closure has become a frequent addition to oral anticoagulation in patients with atrial fibrillation who undergo cardiac surgery. The procedure significantly reduces the risk of stroke and systemic embolism, which may render anticoagulation unnecessary or even harmful when considering the associated increased risk of bleeding. A clinical trial to address the need for anticoagulation after LAA closure is needed. The ATLAAC trial will enroll 1220 patients with atrial fibrillation who have previously undergone surgical LAA closure. Patients will undergo a cardiac CT-scan to determine if LAA closure was successful and patients with successful closure will be randomized to continue or discontinue anticoagulation. The trial will assess the risk of ischemic stroke, peripheral arterial embolism, and major bleeding during the randomized intervention

Conditions

  • Atrial Fibrillation
  • Left Atrial Appendage Absent
  • Anticoagulant Adverse Reaction

Interventions

  • OAC will be discontinued for the duration of the trialDrug

    Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with ischemic strokes, peripheral arterial embolisms and major bleedingsTime frame: After 128 primary outcome events (approx 4 years)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Rigshospitalet

    Copenhagen, Capital Region, Denmark · Not yet recruiting

  • Gentofte Hospital

    Gentofte Municipality, Capital Region, Denmark · Recruiting

  • Regionshospital Gødstrup

    Herning, Central Jutland, Denmark · Not yet recruiting

  • Aalborg university hospital

    Aalborg, North Denmark, Denmark · Not yet recruiting

  • Århus Universitetshospital

    Aarhus, Region Midt, Denmark · Recruiting

  • Odense University Hospital

    Odense, Region Syddanmark, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.